Orion Biotechnology Canada, Ltd.

Orion Biotechnology Canada, Ltd. is a research-driven company based in Canada, specializing in the development of innovative therapeutics targeting metabolic G Protein-Coupled Receptors (GPCRs) for obesity and metabolic disorders. Founded in 2017 and headquartered in Ottawa, Canada, Orion Biotechnology Canada, Ltd. focuses on the research and development of therapeutics aimed at metabolic disorders.

The company has successfully raised USD 11. 5 mn in its Series A funding round led by Keiretsu Forum on June 17, 2021, supporting its innovative therapeutic pipeline. Rudolf Bom is the founder, and Mark Groper serves as the CEO. Orion Biotechnology is focused on the research and development of innovative therapeutics targeting metabolic G Protein-Coupled Receptors (GPCRs), particularly for obesity and metabolic disorders.

The company's primary product candidates include OB-002, an injectable peptide, and OB-003, an oral small molecule, both aimed at modulating the GPR75 receptor, a novel target for obesity treatment. These candidates have shown consistent efficacy in preclinical evaluations and are poised to enter clinical development. Orion’s proprietary PROcisionX™ platform streamlines the drug discovery process, enabling the rapid development of therapeutics from target identification to optimized lead within six months. The company primarily serves the pharmaceutical and biotechnology sectors, collaborating with research institutions and healthcare organizations globally, including significant markets in North America and Europe.

Orion Biotechnology's revenue model is primarily structured around partnerships and collaborations within the pharmaceutical industry, specifically focusing on out-licensing opportunities and R&D collaborations related to its PROcisionX™ platform. Typical transactions may involve licensing agreements where clients gain access to Orion's proprietary technology for the development of their own GPCR-targeting therapeutics. These agreements may also encompass milestone payments based on the progress of clinical trials and sales royalties upon successful commercialization of products. Although specific pricing plans and revenue figures associated with individual products or services are not disclosed, Orion's business model is built on fostering strategic partnerships that leverage its technological innovations and therapeutic developments in obesity and metabolic disorders.

Following the successful fundraising of USD 11. 5 mn in June 2021, Orion Biotechnology Canada, Ltd. plans to utilize this funding to advance its pipeline of precision-engineered therapeutics, including its lead oncology candidate Chemokine Analog. The company aims to extend its proprietary discovery platform and is focused on expanding its presence in North America and Europe, targeting the launch of new products within the next two years.